Cargando…
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg onc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321723/ https://www.ncbi.nlm.nih.gov/pubmed/18044688 |
_version_ | 1782228974317862912 |
---|---|
author | Hodder, Richard Kesten, Steven Menjoge, Shailendra Viel, Klaus |
author_facet | Hodder, Richard Kesten, Steven Menjoge, Shailendra Viel, Klaus |
author_sort | Hodder, Richard |
collection | PubMed |
description | Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV(1) was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV(1) compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS. |
format | Online Article Text |
id | pubmed-3321723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-33217232012-04-10 Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids Hodder, Richard Kesten, Steven Menjoge, Shailendra Viel, Klaus Int J Chron Obstruct Pulmon Dis Original Research Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV(1) was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV(1) compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS. Dove Medical Press 2007-06 2007-06 /pmc/articles/PMC3321723/ /pubmed/18044688 Text en © 2007 Dove Medical Press Limited. All rights reserved |
spellingShingle | Original Research Hodder, Richard Kesten, Steven Menjoge, Shailendra Viel, Klaus Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title | Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title_full | Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title_fullStr | Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title_full_unstemmed | Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title_short | Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
title_sort | outcomes in copd patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321723/ https://www.ncbi.nlm.nih.gov/pubmed/18044688 |
work_keys_str_mv | AT hodderrichard outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids AT kestensteven outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids AT menjogeshailendra outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids AT vielklaus outcomesincopdpatientsreceivingtiotropiumorsalmeterolplustreatmentwithinhaledcorticosteroids |